Literature DB >> 6243860

Nephrotic syndrome associated with adenocarcinoma of the breast.

C H Barton, N D Vaziri, G S Spear.   

Abstract

Although the nephrotic syndrome has been reported in association with a wide variety of neoplastic diseases, it has only rarely been noted as a complication of breast carcinoma. We describe a patient who presented with the nephrotic syndrome and who was subsequently found to have carcinoma of the breast. The findings on renal biopsy were indicative of membranous nephropathy with positive immunofluorescent staining for immunoglobulin G (IgG) and the third component of complement (C3). The nephrotic syndrome completely resolved following successful treatment of the cancer. We have now followed this patient for over two years and there has been no recurrence of tumor or the nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243860     DOI: 10.1016/0002-9343(80)90373-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Crescentic glomerulonephritis and eosinophilic interstitial infiltrates in a patient with hypereosinophilic syndrome.

Authors:  P Richardson; G Dickinson; S Nash; L Hoffman; R Steingart; M Germain
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

Review 2.  Response of paraneoplastic syndromes to antineoplastic therapy.

Authors:  M Markman
Journal:  West J Med       Date:  1986-05

3.  [Drug treatment of chronic glomerulonephritis: pro].

Authors:  K Kühn; J Brodehl; K M Koch; U Helmchen
Journal:  Klin Wochenschr       Date:  1985-09-16

4.  Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.

Authors:  Hiromichi Yoshizawa; Tetsu Akimoto; Katsuhiko Nishino; Makoto Inoue; Chiharu Ito; Shinichi Takeda; Atsushi Kotoda; Kaichiro Tamba; Wako Yumura; Shigeaki Muto; Yoshihiko Ueda; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-03-18       Impact factor: 2.617

5.  Nephrotic syndrome as the marker for underlying malignancy.

Authors:  P E Stevens; D J Rainford
Journal:  J R Soc Med       Date:  1988-07       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.